

PharmaMar presented at AACR

14 new studies on its marine-derived antitumour compounds

- The company of the Zeltia Group presents new data on efficacy, mechanism of action and molecular profile of its portfolio of antitumor compounds
- Zalypsis® in combination therapy shows potent activity against animal models of hepatocellular carcinoma, gastric tumors and bladder
- New preclinical studies confirm the effectiveness of Irvalec® in lung cancer and in combination with other antitumor compounds
- Yondelis® has been particularly active in Ewing's Sarcoma (pediatric tumors) as an inhibitor of the transcription factor EWS-FLI1 type I present in these tumors
- Aplidin® shows good results in *in vitro* and *in vivo* studies against pancreatic cancer and B cell non-Hodgkin's lymphoma
- Two papers describe the new mechanism of action and the molecular profile of a new compound in development, PM01183

Madrid, April 27, 2009: PharmaMar, a biopharmaceutical company of Zeltia Group, ZEL.MC presented the results of 14 new studies on its pipeline of antitumor compounds of marine origin at the 100th Congress of the Annual Conference of the American Association for Cancer Research (AACR), held in Denver, 18-22 April.

Clinical trials provide an update of recent advances made by the company in the development of its pipeline of products against cancer. PharmaMar presented new data on efficacy, mechanism of action and molecular profile of Zalypsis® Irvalec® Aplidin® and PM01183 at the AACR.

In combination therapy, Zalypsis ® shows promising results against hepatocellular carcinoma. The combination of the compound with sorafenib potentiates the antitumor activity of the treatment compared with monotherapy. Zalypsis® in combination with cisplatin, also obtained good results in animal models of gastric and bladder tumors.

Zalypsis ®, currently in Phase II studies, is a novel chemical entity related to the natural marine compound Jorumycine. One of the papers presented at the AACR describes the

innovative mechanism of action of Zalypsis. According to the study, tumors with greater sensitivity to the drug present p53 mutations or deficiency.

PharmaMar also presented at the AACR a series of preclinical studies with Irvalec®, currently in phase II of development for the treatment of non-small cell lung cancer. In two further papers, Irvalec confirmed its promising drug profile against lung cancer. In trials with human tumor cells the compound is particularly powerful when combined with other antitumor compounds. Two new studies define the mechanism of action of Irvalec® and the genetic profile of tumors which show higher response to the treatment.

Also, results were presented that show that Ewing sarcomas (pediatric tumours) with EWS-FLI1 type 1 translocation, the most frequent (65%), respond very well to Yondelis. It was also demonstrated that Yondelis inhibits the transcription of a number of genes controlled by the transcription factor EWS-FLI1 type I.

Finally, two additional preclinical trials presented confirm the effectiveness of Aplidin® in experiments in vitro and in vivo in combination therapy against pancreatic cancer and B-cell non Hodgkin Lymphoma.

Two studies describe the mechanism of action of PM01183, a new compound that shows a peculiar antimetastatic activity, particularly relevant for future exploration in the clinical setting.

PharmaMar

PharmaMar is a biopharmaceutical company of the Spanish Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine derived drugs. PharmaMar has four new compounds in clinical development. Yondelis® has received marketing approval in the European Commission for the treatment of advanced soft tissue sarcoma. Aplidin®, Zalypsis® and Irvalec® are marine-derived new agents in clinical development. PharmaMar has also two molecules in advanced preclinical development and an extensive portfolio of products in research and a robust R & D.

For more information:

Media Relations (tel. +34 91 846 60 00)

Fernando Mugarza

Capital Markets (tel. + 34 91 444 45 00)

Alfonso Hurtado de Mendoza - Florencia Radizza

This press release is also available on the News section at www.pharmamar.com